Bayerische Motoren Werke ADR (BMWYY)

As electric vehicle adoption accelerates across Southwest Ohio, BMW of Cincinnati North has launched a new online EV education guide to help Cincinnati-area drivers understand charging options, ownership costs, and the long-term benefits of driving a BMW electric vehicle.

HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions.

As of March 24, 2026, the global energy transition has reached a critical inflection point, and at the heart of this shift stands Albemarle Corporation (NYSE: ALB). After weathering a tumultuous two-year period defined by a "lithium winter" that saw prices plummet from historic highs, Albemarle has emerged in 2026 as a leaner, more strategically [...]

As of March 24, 2026, Tesla, Inc. (NASDAQ: TSLA) finds itself at a pivotal crossroads, navigating a landscape that looks vastly different from the unbridled growth years of the early 2020s. Once the undisputed monarch of the electric vehicle (EV) revolution, the Austin-based titan is currently grappling with a significant "European Slump"—a contraction in its [...]

For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is being registered in developing mRNA vaccines against cancer, but this progress has come up against a wall of misinformation that could thwart the prospects of this promising intervention.

Gaxos.ai (NASDAQ: GXAI) announced that its portfolio company, America First Defense (AFD), has begun deployment of the Anduril Lattice Platform to expand its counter-swarm UAV and anti-drone defense systems, marking a key milestone in advancing its autonomous defense infrastructure. The integration enhances AFD’s ability to identify, track, assess and respond to evolving unmanned aerial threats, supporting its focus on layered, AI-enabled counter-UAS solutions as demand grows for adaptive, software-defined defense technologies.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors as Soligenix advances multiple programs toward key inflection points.

Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its investigational therapy SGX945 was granted Promising Innovative Medicine (“PIM”) designation by the United Kingdom’s (“UK’s”) Medicines and Healthcare products Regulatory Agency (“MHRA”).

As of March 20, 2026, NVIDIA Corporation (NASDAQ:NVDA) has transcended its origins as a high-end graphics chipmaker to become the foundational architect of the global digital economy. Often referred to by analysts as the "Operating System of AI," NVIDIA’s influence now rivals that of the great industrial giants of the 20th century. The company’s trajectory [...]

Enormous resources are being channeled into studying different ways to support the immune system in its fight against cancer. One emerging approach is the use of oncolytic viruses. This approach seeks to leverage viruses to destroy cancer by attacking and killing its cells.

Tesla investors knew they'd be seeing some new competitors -- but many didn't expect this one.

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers, including doctors, nurse practitioners and nurses have flocked to the Canadian province in search of employment and have secured jobs.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM to implement an FDA-cleared AI platform in its ongoing Parkinson’s disease study, enabling real-time monitoring of symptoms such as bradykinesia, tremor and dyskinesia through wearable and mobile technology, with the data serving as digital biomarkers to enhance disease tracking, support evaluation of buntanetap over the 36-month trial and provide deeper insights into treatment response and future clinical development.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will host a conference call at 8:00 a.m. ET on March 24, 2026, to review financial results for the fiscal year ended Dec. 31, 2025, and provide updates on progress across its drug development programs and the HOPE Therapeutics clinical network, highlighting milestones aligned with its mission to prevent suicide and advance treatments for depression and PTSD.

Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside one digital pathway. That shift toward fully integrated platforms is changing expectations across healthcare, and Earth Science Tech’s (OTC: ETST) is building exposure to that trend through a portfolio that includes telemedicine platforms, compounding pharmacies and related healthcare services.

Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health has approved its line of kinesiology tapes for import and sale, with exclusive distribution partner Innomedica CCB overseeing and financing the regulatory process. The company plans to ramp up marketing efforts in partnership with Innomedica, targeting both its kinesiology tape products and mosquito repellent patch line following the approval.

Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and commercializing therapies and vaccines for rare diseases and unmet medical needs.

NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA’s Bioequivalence Program stating no bioequivalence deficiencies were identified at this time in its Abbreviated New Drug Application, with a preliminary determination ahead of anticipated approval in Summer 2026. The company highlighted its preservative-free ketamine formulation, which excludes benzethonium chloride, as a potential advancement in safety and stability, while continuing to pursue regulatory pathways for broader therapeutic use.

We, Foshan Tiancai Aluminum Co. Ltd., participated in The 16th Zhengzhou International Automobile Exhibition (ZZIAE) , held from June 26th to June 28th, 2025 . Our booth was located at 2C371 2C365 . During this exhibition, we showcased our newly developed products. We welcome you to visit our booth and explore the innovative solutions we have on display.

Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The resultant damage to healthy tissues usually triggers side effects that often become severe, necessitating discontinuation of therapy or making quality of life worse. Scientists have been looking for better treatments that only impact malignant cells and leave healthy cells unaffected. A new preclinical study documents one such discovery leveraging the use of a mirror-image molecule.

OXNARD, CA - March 16, 2026 - PRESSADVANTAGE - Prestige Bodyworks, a leading collision repair facility in Oxnard, California, continues to advance industry standards through its comprehensive approach to vehicle...

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined, have the potential to improve outcomes and results for cancer patients.

Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent years. However, not all malignancies respond to these therapies, and those that do often become resistant, or are discontinued due to adverse reactions within the immune system. Now, researchers have shown that gut microbiota are one of the key factors influencing the success of immunotherapy targeting PD-L1 and PD-1 gene expression.

Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, announced the acquisition of Ignite Proteomics LLC, a commercial-stage precision oncology company focused on improving therapy selection in cancer care through functional proteomics. Ignite’s Reverse Phase Protein Array platform is designed to measure protein expression and activity directly from tumor samples, providing insight into whether targeted therapies are likely to be effective, information that may not be captured by genomic testing alone. Under the terms of the transaction, Aditxt acquired Ignite through the issuance of 36,000 shares of newly designated Series A-2 Convertible Preferred Stock with an aggregate stated value of $36 million, with Ignite to operate as a subsidiary within Aditxt’s oncology initiatives.

As of March 12, 2026, the global aluminum market is navigating a period of intense volatility and structural shifts, with prices on the London Metal Exchange (LME) surging to nearly four-year highs between $3,269 and $3,544 per tonne. While the industry entered the year with cautious optimism, a